Systematic literature review investigating whether methotrexate causes chronic pulmonary fibrosis.
作者信息
Quah Ed, Amoasii Constanta, Mudawi Tareg, Dawson Julie
机构信息
St Helens and Knowsley Trust Hospitals, UK.
出版信息
Future Healthc J. 2019 Jun;6(Suppl 2):4. doi: 10.7861/futurehosp.6-2s-s4.
Abstract
摘要
相似文献
1
Systematic literature review investigating whether methotrexate causes chronic pulmonary fibrosis.
Future Healthc J. 2019 Jun;6(Suppl 2):4. doi: 10.7861/futurehosp.6-2s-s4.
2
Review of existing evidence demonstrates that methotrexate does not cause liver fibrosis.
J Investig Med. 2022 Oct;70(7):1452-1460. doi: 10.1136/jim-2021-002206. Epub 2022 Aug 24.
3
Histopathological Features of Methotrexate Induced Pulmonary Lesions in Rheumatoid Arthritis Patients: A Systematic Review of Case Reports.
Open Access Maced J Med Sci. 2017 Apr 8;5(2):266-270. doi: 10.3889/oamjms.2017.049. eCollection 2017 Apr 15.
4
Efficacy of clarithromycin as a protective agent in the methotrexate-induced pulmonary fibrosis model.
Kardiochir Torakochirurgia Pol. 2018 Dec;15(4):209-212. doi: 10.5114/kitp.2018.80915. Epub 2018 Dec 31.
5
Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests.
Rheumatology (Oxford). 2002 Mar;41(3):262-7. doi: 10.1093/rheumatology/41.3.262.
6
Traditional Chinese medicine for the treatment of pulmonary fibrosis: A protocol for systematic review and meta-analysis of overview.
Medicine (Baltimore). 2020 Jul 31;99(31):e21310. doi: 10.1097/MD.0000000000021310.
7
Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.
J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:12-8. doi: 10.1111/j.1468-3083.2011.03991.x.
8
Methotrexate-induced diffuse interstitial pulmonary fibrosis.
South Med J. 1979 Mar;72(3):313-8. doi: 10.1097/00007611-197903000-00023.
9
Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review.
Clin Rheumatol. 2011 Oct;30(10):1379-84. doi: 10.1007/s10067-011-1765-7. Epub 2011 May 26.
10
Involvement of epithelial-mesenchymal transition in methotrexate-induced pulmonary fibrosis.
J Toxicol Sci. 2014 Apr;39(2):319-30. doi: 10.2131/jts.39.319.
引用本文的文献
1
Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections.
J Clin Med. 2023 Oct 9;12(19):6419. doi: 10.3390/jcm12196419.
2
Immunotargets and Therapy for Prurigo Nodularis.
Immunotargets Ther. 2022 Apr 26;11:11-21. doi: 10.2147/ITT.S316602. eCollection 2022.
3
Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome Manifesting as Lymphocytic Interstitial Pneumonia and Treatment-Resistant Bullous Pemphigoid.
Pediatr Allergy Immunol Pulmonol. 2021 Jun;34(2):76-79. doi: 10.1089/ped.2020.1307.
本文引用的文献
1
Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis.
Clin Rheumatol. 2017 Jul;36(7):1493-1500. doi: 10.1007/s10067-017-3707-5. Epub 2017 Jun 6.
2
Chronic pulmonary toxicity of methotrexate and rheumatoid arthritis.
Rheumatology (Oxford). 2003 Jun;42(6):802-3; author reply 803-4. doi: 10.1093/rheumatology/keg188.
3
Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests.
Rheumatology (Oxford). 2002 Mar;41(3):262-7. doi: 10.1093/rheumatology/41.3.262.
4
Pulmonary complications following methotrexate therapy.
J Am Acad Dermatol. 1987 Feb;16(2 Pt 1):373-5. doi: 10.1016/s0190-9622(87)70052-8.
5
Progressive interstitial lung disease from prolonged methotrexate therapy.
Arch Dermatol. 1978 Dec;114(12):1800-2.
6
Methotrexate-induced diffuse interstitial pulmonary fibrosis.
South Med J. 1979 Mar;72(3):313-8. doi: 10.1097/00007611-197903000-00023.
Zotero 插件